Tzvetanov P, Nicoloff G, Rousseff R, Christova P
Department of Neurology and Neurosurgery, Medical University of Pleven, Georgi Kochev Street 8A, Pleven 5800, Bulgaria.
Clin Neurol Neurosurg. 2008 Mar;110(3):239-44. doi: 10.1016/j.clineuro.2007.11.003. Epub 2008 Feb 21.
To investigate whether elastin-derived peptides (EDP) are detectable in the cerebrospinal fluid (CSF) of healthy controls and of patients with acute brain ischemia and if so to assess possible trends in EDP levels in different groups of ischemic stroke patients (small-vessel disease vs. other ischemic strokes; first-ever vs. recurrent stroke).
Levels of EDP were determined by ELISA in blood sera and CSF of 80 patients with acute ischemic stroke (mean age 61.5+/-10.8; age range 47-70; 22 women) and in 15 healthy age- and sex-matched controls (mean age 57.3+/-13.4; age range 50-65). The patients were divided into a group with first ever lacunar stroke (27); first ever non-lacunar ischemic stroke (27) and recurrent stroke (26). EDP were measured early (mean 7 days, range 1-15) after stroke onset.
Serum EDP levels were mildly higher in recurrent strokes as compared to first ever lacunar lesion and controls. However, in the CSF the concentrations of EDP in stroke patients were strongly elevated (from 2 up to 30 times depending on subgroup) as compared with healthy subjects. The highest level of EDP in CSF and in the serum was found in recurrent strokes. Subgroup analysis revealed a trend for significantly higher EDP concentrations in CSF in lacunar and recurrent stroke as compared with non-lacunar.
This study is the first application of elastin peptide measurement to human CSF and stroke patients. The increased levels of EDP were detected in CSF of patients with lacunar and recurrent strokes.
研究在健康对照者及急性脑缺血患者的脑脊液（CSF）中是否可检测到弹性蛋白衍生肽（EDP），若可检测到，则评估不同组缺血性卒中患者（小血管病与其他缺血性卒中；首次卒中与复发性卒中）中EDP水平的可能变化趋势。
采用酶联免疫吸附测定法（ELISA）测定80例急性缺血性卒中患者（平均年龄61.5±10.8岁；年龄范围47 - 70岁；女性22例）以及15例年龄和性别匹配的健康对照者（平均年龄57.3±13.4岁；年龄范围50 - 65岁）血清和脑脊液中的EDP水平。患者分为首次腔隙性卒中组（27例）、首次非腔隙性缺血性卒中组（27例）和复发性卒中组（26例）。在卒中发作后早期（平均7天，范围1 - 15天）测定EDP。
与首次腔隙性病变及对照组相比，复发性卒中患者的血清EDP水平略有升高。然而，与健康受试者相比，卒中患者脑脊液中EDP浓度显著升高（根据亚组不同，升高2至30倍）。脑脊液和血清中EDP水平最高的是复发性卒中患者。亚组分析显示，与非腔隙性卒中相比，腔隙性卒中和复发性卒中患者脑脊液中EDP浓度有显著升高的趋势。
本研究首次将弹性蛋白肽检测应用于人类脑脊液及卒中患者。在腔隙性卒中和复发性卒中患者的脑脊液中检测到EDP水平升高。
